These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25245442)

  • 21. Carcinocythemia. A terminal manifestation of metastatic breast cancer.
    Aboulafia DM
    West J Med; 1992 Dec; 157(6):672-4. PubMed ID: 1335633
    [No Abstract]   [Full Text] [Related]  

  • 22. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer.
    Hartkopf AD; Wagner P; Wallwiener D; Fehm T; Rothmund R
    Anticancer Res; 2011 Mar; 31(3):979-84. PubMed ID: 21498725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients.
    Soria JC; Gauthier LR; Raymond E; Granotier C; Morat L; Armand JP; Boussin FD; Sabatier L
    Clin Cancer Res; 1999 May; 5(5):971-5. PubMed ID: 10353728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment.
    Green TL; Cruse JM; Lewis RE; Craft BS
    Exp Mol Pathol; 2013 Oct; 95(2):174-9. PubMed ID: 23831428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the effect of surgery on the kinetics of circulating tumour cells in patients with operable breast cancer based on cytokeratin-19 mRNA detection.
    Daskalakis M; Mavroudis D; Sanidas E; Apostolaki S; Askoxylakis I; de Bree E; Georgoulias V; Melissas J
    Eur J Surg Oncol; 2011 May; 37(5):404-10. PubMed ID: 21376504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Information from CTC measurements for metastatic breast cancer prognosis-we should do more than selecting an "optimal cut point".
    Fehm T; Sauerbrei W
    Breast Cancer Res Treat; 2010 Jul; 122(1):219-20. PubMed ID: 20130980
    [No Abstract]   [Full Text] [Related]  

  • 28. Correlation among [18F]fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancer.
    Saad A; Kanate A; Sehbai A; Marano G; Hobbs G; Abraham J
    Clin Breast Cancer; 2008 Aug; 8(4):357-61. PubMed ID: 18757264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there a role for circulating tumor cells in the management of breast cancer?
    Hayes DF; Smerage J
    Clin Cancer Res; 2008 Jun; 14(12):3646-50. PubMed ID: 18559576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis.
    Martín M; García-Sáenz JA; Maestro De las Casas ML; Vidaurreta M; Puente J; Veganzones S; Rodríguez-Lajusticia L; De la Orden V; Oliva B; De la Torre JC; López-Tarruella S; Casado A; Sastre J; Díaz-Rubio E
    Anticancer Res; 2009 Oct; 29(10):4185-7. PubMed ID: 19846970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
    Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
    Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
    Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
    Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
    Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of circulating urothelial cancer cells in the blood using the CellSearch System.
    Naoe M; Ogawa Y; Morita J; Omori K; Takeshita K; Shichijyo T; Okumura T; Igarashi A; Yanaihara A; Iwamoto S; Fukagai T; Miyazaki A; Yoshida H
    Cancer; 2007 Apr; 109(7):1439-45. PubMed ID: 17326057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.
    Kallergi G; Agelaki S; Kalykaki A; Stournaras C; Mavroudis D; Georgoulias V
    Breast Cancer Res; 2008; 10(5):R80. PubMed ID: 18822183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Back with a vengeance: microvascular tumor embolism.
    Yunokawa M; Tsuta K; Tanaka T; Nara E; Koizumi F; Ito J; Sekine S; Fujiwara Y; Tamura K
    Am J Med; 2015 Aug; 128(8):834-6. PubMed ID: 25912204
    [No Abstract]   [Full Text] [Related]  

  • 38. Circulating cancer cells in division in an early breast cancer patient.
    Serrano MJ; Nadal R; Lorente JA; Salido M; Rodríguez R; Rodríguez M; Macià M; Sánchez-Rovira P; Corominas JM; González L; Vera L; Albanell J; Solé F
    Ann Oncol; 2011 Sep; 22(9):2150-2151. PubMed ID: 21743104
    [No Abstract]   [Full Text] [Related]  

  • 39. Intratumor and circulating clonal heterogeneity shape the basis of precision breast cancer therapy.
    Ziogas DE; Spiliotis J; Lykoudis EG; Zografos GC; Roukos DH
    Future Oncol; 2017 Jan; 13(2):113-116. PubMed ID: 27581662
    [No Abstract]   [Full Text] [Related]  

  • 40. Circulating tumor cells in metastatic breast cancer: the need for a standardized approach.
    De Mattos-Arruda L; Elattar I; Azim HA
    Ann Oncol; 2011 Jan; 22(1):234. PubMed ID: 20940412
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.